Articles

Research was recently published inDiabetes Care as a Phase II study to determine optimal dosing, tolerability and efficacy of a new, once-weekly DPP-4 inhibitor called omarigliptin. Over 12 weeks, the researchers looked at HbA1C, 2-hour postprandial glucose and fasting glucose. Currently, the DPP-4 inhibitors on the market are all once-daily. …

Thiazolidinediones (TZDs), rosiglitazone and pioglitazone, have been shown to increase fracture risk in women after a year of TZD use; however, there has been little data available on the effects of the discontinuation of TZD. This longitudinal observational cohort study used data from an ancillary study of skeletal health within …

Mineralocorticoid receptor antagonists (MRAs) are often used with a renin-angiotensin system (RAS) blocker to further reduce proteinuria in patients with CKD. However, eplerenone and spironolactone increase the risk of hyperkalemia in these patients. Finerenone (BAY94-8862) is a new nonsteroidal MRA that has better receptor selectivity than spironolactone, associating with lower …

A Mediterranean diet is considered to be ideal for healthy nutrition. It is typically composed of fruits, vegetables, cereals, fish, moderate wine consumption, and limited intake of dairy products and red meat. Furthermore, there are several studies showing that this type of diet is connected with reduced risk of cardiovascular …

In recent years, there has been a worldwide focus on metabolic syndrome to identify specific factors that may contribute to the development of diabetes and obesity. An interesting factor that researchers are exploring is eating habits, particularly, the speed of eating. Therefore, a study was performed to understand the relationship …

For newly diagnosed type 2 diabetes patients, metformin is the first-line drug of choice. It can be used alone, in combination with other oral antidiabetic drugs, or in addition to insulin. Its precise mechanism of action is as of yet unknown, but a new study published in Diabetes Care posits …

Bone mineral density at hip and lower spine may also decrease.

Single-tablet approach hoped to boost treatment compliance and help patients better manage condition.. Synjardy contains empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and metformin, a biguanide. It is not for the treatment of type 1 diabetes or diabetic ketoacidosis. The drug label contains a boxed warning on the risk of …

Risk warning, precaution added to labels of all drugs in this class…   FDA warned recently that DPP-4 inhibitors could cause severe and disabling joint pain. The agency has added a new warning and precaution about this risk to the labels of all drugs in this class. If patients experience …

Study cites vascular, nonvascular causes…. The purpose of this study was to assess the odds of all-cause mortality in individuals with diabetic foot ulceration (DFU) compared with those with diabetes and no history of DFU. In addition, we sought to determine the strength of association of DFU with cardiovascular and …